Dabigatran etexilate Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Dabigatran etexilate is an orally administered pro-drug of dabigatran,
which is a direct inhibitor of thrombin and a potent anticoagulant. The serine protease thrombin is the final mediator in the coagulation cascade
that leads to the production of fibrin, the main protein component of
blood clots. Thrombin is also a potent activator of platelets. Consequently, thrombin inhibitors have found utility as anticoagulants in
treating arterial and venous thrombosis.
Warfarin, although orally available, has a
narrow therapeutic index and requires frequent monitoring and dosage
adjustment. Low-molecular-weight heparins provide better safety profile
and less inter-patient variability; however, these agents are only available
for parenteral administration. Direct thrombin inhibitors (DTIs) are a
new class of anticoagulants that act by directly binding to thrombin at its
catalytic or fibrinogen-binding sites, or both. Unlike the heparins, DTIs do not require the activation of secondary factors such as antithrombin to derive their activity, which makes their action more predictable. In addition, their ability to inhibit both free and clot-bound thrombin predisposes them for enhanced anticoagulation effect.
Verwenden
Dabigatran Etexilate is an oral anticoagulant and direct thrombin inhibitor.
Definition
ChEBI: An aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-{N'-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amino group of
thyl N-pyridin-2-yl-beta-alaninate. A prodrug for dabigatran, a thrombin inhibitor and anticoagulant which is used for the prevention of stroke and systemic embolism.
Dabigatran etexilate Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
